Xuanzhu Biological -B (02575.HK): The filing for a new indication for the treatment of gastroesophageal reflux disease with Anilarzole Sodium has been accepted by the National Medical Products Administration.

The Zhitong Finance APP News, Xuanzhu Biology-B (02575.HK) announced that the company's independently developed Class 1 innovative drug Annerazone sodium enteric-coated tablets (trade name: Anjiuwei) for the treatment of adult reflux esophagitis (RE) has recently been officially accepted by the National Medical Products Administration (NMPA) for a new indication marketing authorization application (NDA).